Vorapaxar is the first PAR-1 antagonist that was approved by the US Food and Drug Administration (in US and Europe) in May 2014 to reduce the risk of MI, stroke, and cardiovascular death and for the revascularization in patients with a previous MI or PAD (US). Here, F2R is linked to Stroke.